Aripiprazole/phenelzine/quetiapine Reactions 1680, p56 - 2 Dec 2017 Orthostasis: case report A 54-year-old man developed orthostasis during treatment with aripiprazole, phenelzine and quetiapine [routes, time to reaction onset not stated and outcome not stated]. The man was diagnosed with major depression with psychotic features, which was in partial remission. He received treatment with clomipramine augmented with quetiapine up to 1200 mg/day. No significant symptomatic response was observed. Aripiprazole up to 15 mg/day was started as an adjunctive therapy on 23 January 2015. Only modest benefit was observed with aripiprazole. Consequently, therapy with phenelzine 15mg every morning was initiated on 10 April 2015. The treatment also included aripiprazole and quetiapine 1000 mg/day. The dose of quetiapine was gradually reduced to 300mg at bedtime due to the risk of orthostasis. The doses of phenelzine and aripiprazole were steadily increased. In June 2015, he was on aripiprazole 20 mg/day, quetiapine 300mg at bedtime and phenelzine 30mg thrice a day. A significant antidepressant response was achieved. Subsequently, he had complaints of orthostasis. The man’s therapy with phenelzine was discontinued on 09 September 2015 as a result of falls. Later, levomilnacipran was added to the therapy, but failed. Author comment: "While the combination of an atypical antipsychotic and [MAO inhibitors] may carry a risk of orthostasis in middle-aged and older patients, concerns about [serotonin syndrome] should not be the factor preventing its use." Meyer JM, et al. Augmentation of phenelzine with aripiprazole and quetiapine in a treatment-resistant patient with psychotic unipolar depression: Case report and literature review. CNS Spectrums 22: 391-396, No. 5, Oct 2017. Available from: URL: - USA 803285141 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial